Literature DB >> 10468284

Fractionated gamma-irradiation renders tumour cells more responsive to apoptotic signals through CD95.

M A Sheard1, P H Krammer, J Zaloudik.   

Abstract

Signals through the CD95 surface receptor can specifically induce apoptosis. Some tumour cell lines are sensitive to CD95 signals, and insensitive cells can be converted to a sensitive phenotype if given appropriate treatment. To determine whether the apoptotic response of tumour cells to signalling through CD95 might be enhanced by ionizing irradiation, carcinoma cells were treated with either single-dose or fractionated gamma-irradiation. The response to treatment with an agonist anti-CD95 antibody was enhanced by pretreatment with either a single large dose or daily fractionated radiation. Fractionated irradiation induced cumulative and prolonged up-regulation of CD95 expression in cell lines bearing functional p53. Since two of four cell lines exhibiting heightened responsiveness to CD95-mediated signals following fractionated irradiation express mutant p53 and displayed little or no up-regulation of CD95, enhanced responsiveness did not correlate with p53 status and CD95 up-regulation. Continuous inhibition of CD95/CD95-ligand interactions during fractionated irradiation provided no protective effect to cells, arguing that autologous CD95/CD95-ligand interactions did not contribute to the direct lethal effect of irradiation. We conclude that fractionated gamma-irradiation provides an extended period of time when carcinoma cells are more responsive to CD95-mediated signals in vitro.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10468284      PMCID: PMC2363128          DOI: 10.1038/sj.bjc.6690585

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression.

Authors:  L B Owen-Schaub; W Zhang; J C Cusack; L S Angelo; S M Santee; T Fujiwara; J A Roth; A B Deisseroth; W W Zhang; E Kruzel
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

Review 2.  Recent advances in radiation oncology.

Authors:  A S Lichter; T S Lawrence
Journal:  N Engl J Med       Date:  1995-02-09       Impact factor: 91.245

3.  Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.

Authors:  M Müller; S Strand; H Hug; E M Heinemann; H Walczak; W J Hofmann; W Stremmel; P H Krammer; P R Galle
Journal:  J Clin Invest       Date:  1997-02-01       Impact factor: 14.808

4.  Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells.

Authors:  M Jäättelä; M Benedict; M Tewari; J A Shayman; V M Dixit
Journal:  Oncogene       Date:  1995-06-15       Impact factor: 9.867

5.  Expression of the Fas ligand in cells of T cell lineage.

Authors:  T Suda; T Okazaki; Y Naito; T Yokota; N Arai; S Ozaki; K Nakao; S Nagata
Journal:  J Immunol       Date:  1995-04-15       Impact factor: 5.422

6.  Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells.

Authors:  Y Oshimi; S Oda; Y Honda; S Nagata; S Miyazaki
Journal:  J Immunol       Date:  1996-10-01       Impact factor: 5.422

7.  Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis.

Authors:  C M Eischen; J D Schilling; D H Lynch; P H Krammer; P J Leibson
Journal:  J Immunol       Date:  1996-04-15       Impact factor: 5.422

8.  Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)

Authors:  J Dhein; H Walczak; C Bäumler; K M Debatin; P H Krammer
Journal:  Nature       Date:  1995-02-02       Impact factor: 49.962

9.  Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells.

Authors:  C Friesen; I Herr; P H Krammer; K M Debatin
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

Review 10.  Proteolysis and the biochemistry of life-or-death decisions.

Authors:  J Ashkenas; Z Werb
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Immunomodulatory effects of radiation: what is next for cancer therapy?

Authors:  Anita Kumari; Samantha S Simon; Tomika D Moody; Charlie Garnett-Benson
Journal:  Future Oncol       Date:  2015-12-01       Impact factor: 3.404

2.  Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas.

Authors:  F Heinzelmann; W Bethge; D W Beelen; M Engelhard; N Kröger; P Dreger; D Niederwieser; J Finke; D Bunjes; J Tischer; G Kobbe; E Holler; M Bornhäuser; M Stelljes; H Baurmann; A Müller; I Haubitz; H Schrezenmeier; C Müller; H Ottinger
Journal:  Bone Marrow Transplant       Date:  2016-02-08       Impact factor: 5.483

3.  The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12.

Authors:  Eva Roubalová; Veronika Kvardová; Roman Hrstka; Sárka Borilová; Eva Michalová; Lenka Dubská; Petr Müller; Petr Sova; Borivoj Vojtesek
Journal:  Invest New Drugs       Date:  2009-06-05       Impact factor: 3.850

4.  Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways.

Authors:  Victoria Ifeadi; Charlie Garnett-Benson
Journal:  PLoS One       Date:  2012-02-28       Impact factor: 3.240

Review 5.  Gene therapy for carcinoma of the breast: Pro-apoptotic gene therapy.

Authors:  J Gómez-Navarro; W Arafat; J Xiang
Journal:  Breast Cancer Res       Date:  1999-12-17       Impact factor: 6.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.